Morgan Stanley Raises IQVIA (NYSE:IQV) Price Target to $280.00 (2024)

IQVIA (NYSE:IQV - Get Free Report) had its price objective boosted by Morgan Stanley from $270.00 to $280.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an "overweight" rating on the medical research company's stock. Morgan Stanley's target price would suggest a potential upside of 17.25% from the company's previous close.

A number of other research firms have also recently issued reports on IQV. UBS Group raised their target price on IQVIA from $295.00 to $300.00 and gave the company a "buy" rating in a research note on Tuesday. Barclays lifted their target price on IQVIA from $255.00 to $275.00 and gave the company an "overweight" rating in a research note on Tuesday. Robert W. Baird increased their price target on IQVIA from $235.00 to $251.00 and gave the stock a "neutral" rating in a research note on Tuesday. Truist Financial lifted their price objective on shares of IQVIA from $292.00 to $300.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Monday, July 15th. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $265.00.

View Our Latest Research Report on IQV

IQVIA Stock Down 2.6 %

Shares of IQV traded down $6.43 during midday trading on Tuesday, hitting $238.80. The company had a trading volume of 1,918,130 shares, compared to its average volume of 1,082,404. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73. The company's 50 day moving average price is $219.86 and its 200 day moving average price is $229.08. The stock has a market cap of $43.51 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 2.06 and a beta of 1.49.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The business's revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.22 EPS. On average, equities research analysts predict that IQVIA will post 10.11 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. AdvisorNet Financial Inc grew its holdings in IQVIA by 327.6% during the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company's stock valued at $29,000 after purchasing an additional 95 shares during the last quarter. Rise Advisors LLC bought a new position in IQVIA in the 1st quarter worth $31,000. Versant Capital Management Inc lifted its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock worth $26,000 after acquiring an additional 110 shares during the last quarter. Riverview Trust Co acquired a new stake in shares of IQVIA in the first quarter valued at about $32,000. Finally, Opal Wealth Advisors LLC bought a new position in shares of IQVIA in the second quarter worth about $27,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

• Five stocks we like better than IQVIA
• Why Understanding Call Option Volume is Essential to Successful Options Trading
• ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
• What is a SEC Filing?
• Leading Beverage Company's Stock Bubbles Higher: Rally Ahead
• Short Selling: How to Short a Stock
• Can This Meme Stock Stage One Last Rally?

Should you invest $1,000 in IQVIA right now?

Before you consider IQVIA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.

While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here